Data-Driven Decision-Making in Advanced Breast Cancer: HR+ Breast Cancer Updates

Expert panelists share their perspectives on best practices for molecular profiling in patients diagnosed with early-stage breast cancer.

A broad look at the role of Ki67 expression in informing the selection of therapy for patients with early-stage HR+ breast cancer.

Key opinion leaders in breast cancer management discuss Ki67 and the monarchE trial, which analyzed abemaciclib therapy in the HR+ space.

A brief review of prevalent clinical trials in the early-stage HR+ breast cancer paradigm and how they help to inform treatment decision-making.

Shifting their focus to HR+ metastatic disease, expert panelists consider the importance of molecular profiling and first-line treatment options.

Expert perspectives on factors that aid in the selection of optimal first-line therapy for patients with HR+ metastatic breast cancer.

A brief review of the role molecular profiling plays at a patient’s relapse with HR+ metastatic breast cancer.

Key opinion leaders consider when it is appropriate to continue CDK4/6 inhibition at progression of disease in the setting of HR+ metastatic breast cancer.

Shared insight on the selection of endocrine partners while managing patients in the relapsed/refractory setting of HR+ metastatic breast cancer.

Comprehensive discussion on novel treatment modalities in HR+ metastatic breast cancer and insight to when it is appropriate to select these agents.

Closing out their discussion on HR+ breast cancer management, expert panelists share their excitement for the evolving treatment paradigm.